首页 | 本学科首页   官方微博 | 高级检索  
检索        


Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
Institution:1. Department of Thoracic-Cardio Surgery, The Fourth Medical Center of PLA General Hospital, Beijing, China;2. Department of Thoracic Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China;3. Ningbo Diagnostic Pathology Center, Ningbo, China;4. Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada;5. Karmanos Cancer Institute, Wayne State University, Detroit, MI;6. Nanjing Geneseeq Technology Inc, Nanjing, China;7. School of Public Health, Nanjing Medical University, Nanjing, China;8. National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;9. Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange, CA
Abstract:
Keywords:Comprehensive genomic profiling  EGFR TKI resistance  Next generation sequencing  Non–small-cell lung cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号